FACS analysis of leukemic mononuclear cells infiltrating the liver of founder mouse no. 13, comparison of hematologic parameters of transgenic progeny of no. 22, and molecular certification of p230 Bcr/Abl expression. (A) Surface marker analysis of leukemic cells infiltrating the liver of founder no. 13. (B) Comparison of hematologic parameters in the transgenic mice (n = 20; Tg, •) and nontransgenic controls (n = 10; C, ○) from 5 months to 15 months. The data are shown as the mean values and standard deviations for each group. Time course of WBC count, platelet (Plt) count, the percentage (%) of granulocytes, and hemoglobin (Hb) are shown. **P < .01; ***P < .001. (C) Northern blot analysis of p230 Bcr/Abl mRNA in tissues from no. 13 and no. 22 offspring. Lane K562: K562 cells as positive control; lane 32D: mouse 32D cells as negative control; lane liver no. 13: liver cells of no. 13; lane spleen no. 22: spleen cells of no. 22; lane spleen no. 13: spleen cells of no. 13; lane bone marrow no. 22: bone marrow cells of no. 22. The bottom bar shows the bands of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA as an internal control. (D) P230 Bcr/Abl transgene product and (E) kinase activity of the p230 Bcr/Abl transgene product of the splenic cells. The expressed and phosphorylated P230 Bcr/Abl transgene products are indicated by arrows, and the positions of protein markers are shown on the right. The splenic cells of a 3-month-old F1 transgenic mouse were subjected to Western blot and immunoprecipitation analyses.